statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PFG Investments LLC bought a new stake in Verona Pharma plc (NASDAQ:VRNA  Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The...

17,800 Shares in Verona Pharma plc (NASDAQ:VRNA) Purchased by PFG Investments LLC

Verona Pharma plc (NASDAQ:VRNA  Get Free Report) shares fell 7.6% during mid-day trading on Thursday . The company traded as low as $15.42 and last traded at $15.42. 80,327 shares changed...

Verona Pharma (NASDAQ:VRNA) Stock Price Down 7.6%

This is a Bearish indicator signaling VRNA's price could decline from here. Traders may explore shorting the stock or put options...

Verona Pharma (VRNA, $16.73) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 7, 2024

This indicator may be signaling that VRNA's price has further to drop, since it moved below its price 14 days ago. Traders may consider selling the stock, shorting the stock, or exploring put options...

Verona Pharma plc (VRNA, $16.73) entered Downtrend as Momentum indicator drops below 0 level on Mar 07, 2024

HC Wainwright restated their buy rating on shares of Verona Pharma (NASDAQ:VRNA  Free Report) in a report published on Monday morning, Benzinga reports. They currently have a $32.00 target...

HC Wainwright Reiterates "Buy" Rating for Verona Pharma (NASDAQ:VRNA)

This is a signal that VRNA's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

Verona Pharma (VRNA, $16.82) Stochastic Oscillator left the oversold zone on March 06, 2024

Verona Pharma plc (VRNA, $16.97) entered Downtrend as Momentum indicator drops below 0 level on Mar 05, 2024

This price move could indicate a change in the trend, and may be a sell signal for investors...

Verona Pharma (VRNA, $17.28) price exceeded its 50-day Moving Average on March 04, 2024

Verona Pharma (VRNA Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Ram Selvaraju from H.C...

Buy Rating Affirmed on Verona Pharma Ahead of Ensifentrine's Expected FDA Approval and Strong Financial Standing

LONDON and RALEIGH, N.C., March 04, 2024 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) ( Verona Pharma or the Company ), announces Mr. Andrew Fisher has today joined the Company as General...

Andrew Fisher Joins Verona Pharma as General Counsel

Verona Pharma Plc engages in the development and commercialization of therapeutics for the treatment of respiratory diseases. It focuses on developing inhaled ensifentrine for the maintenance treatment of chronic obstructive pulmonary disease. The company was founded by Michael J. A. Walker and Clive P. Page on February 24, 2005 and is headquartered in London, the United Kingdom.

Volume	100.00
52-Wk High	$23.81
52-Wk Low	$11.83

VRNA Verona Pharma plc American Depositary

About

Feed

News

Sentiment

Earnings

Fundamentals